journal
https://read.qxmd.com/read/37771619/update-on-clinical-trials-for-nonalcoholic-steatohepatitis
#21
JOURNAL ARTICLE
Rohit R Nathani, Meena B Bansal
Tremendous effort has been put forth over the past 2 decades in understanding the pathophysiology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). Although multiple potential targets for drug development exist, there have been no approved therapies for NAFLD/NASH. Lipotoxicity, owing to increased delivery of fatty acids to the liver, and hepatic de novo lipogenesis are key drivers of disease pathogenesis. Moreover, genetics, environmental factors, and comorbid conditions converge to determine disease progression in individual patients...
July 2023: Gastroenterology & Hepatology
https://read.qxmd.com/read/37771618/treatment-of-genital-crohn-s-disease-with-upadacitinib-in-a-male-child-a-case-report
#22
JOURNAL ARTICLE
Athos Bousvaros, Birgitta A R Schmidt, Michael Kurtz
No abstract text is available yet for this article.
July 2023: Gastroenterology & Hepatology
https://read.qxmd.com/read/37771617/nonalcoholic-steatohepatitis-drug-development
#23
JOURNAL ARTICLE
Gary R Lichtenstein
No abstract text is available yet for this article.
July 2023: Gastroenterology & Hepatology
https://read.qxmd.com/read/37771616/current-status-and-future-course-of-disposable-component-and-single-use-duodenoscopes
#24
JOURNAL ARTICLE
Nauzer Forbes
No abstract text is available yet for this article.
July 2023: Gastroenterology & Hepatology
https://read.qxmd.com/read/37719891/potential-use-of-artificial-intelligence-in-the-histologic-assessment-of-nonalcoholic-steatohepatitis
#25
JOURNAL ARTICLE
Quentin M Anstee
No abstract text is available yet for this article.
June 2023: Gastroenterology & Hepatology
https://read.qxmd.com/read/37706191/the-path-to-improving-diversity-equity-and-inclusion-in-endoscopy
#26
JOURNAL ARTICLE
Jennifer A Christie
No abstract text is available yet for this article.
June 2023: Gastroenterology & Hepatology
https://read.qxmd.com/read/37706190/insights-into-conditions-that-overlap-with-irritable-bowel-syndrome
#27
JOURNAL ARTICLE
Gerald Holtmann
No abstract text is available yet for this article.
June 2023: Gastroenterology & Hepatology
https://read.qxmd.com/read/37706189/exploring-clostridioides-difficile-infection-and-microbiome-therapeutics
#28
JOURNAL ARTICLE
Gary R Lichtenstein
No abstract text is available yet for this article.
June 2023: Gastroenterology & Hepatology
https://read.qxmd.com/read/37706188/pain-management-in-liver-disease
#29
JOURNAL ARTICLE
James P Hamilton
No abstract text is available yet for this article.
June 2023: Gastroenterology & Hepatology
https://read.qxmd.com/read/37706187/clostridioides-difficile-infection-landscape-and-microbiome-therapeutics
#30
JOURNAL ARTICLE
Brent J Gawey, Sahil Khanna
Clostridioides difficile infection (CDI) is the leading cause of hospital-acquired diarrhea and is common in the community. Both younger individuals who may be healthy otherwise and older individuals with comorbid conditions are at risk for developing CDI, with the predominant risk factor being antibiotic use. Unlike other gastrointestinal infections, CDI is not self-limited, requires antimicrobial therapy, and tends to recur at high rates even without additional risk factor exposure. The goals of CDI management include controlling active symptoms and using a recurrence prevention strategy such as a narrow-spectrum antibiotic, tapered and pulsed regimens, antibody- based therapies (directed against toxin B), or microbiome restoration...
June 2023: Gastroenterology & Hepatology
https://read.qxmd.com/read/37706186/current-approach-to-postoperative-crohn-s-disease
#31
JOURNAL ARTICLE
Miguel Regueiro
No abstract text is available yet for this article.
June 2023: Gastroenterology & Hepatology
https://read.qxmd.com/read/37706185/understanding-the-current-approaches-in-the-management-of-ibs-c-a-case-study
#32
JOURNAL ARTICLE
Anthony J Lembo
No abstract text is available yet for this article.
June 2023: Gastroenterology & Hepatology
https://read.qxmd.com/read/37799459/racial-and-ethnic-disparities-in-inflammatory-bowel-disease
#33
JOURNAL ARTICLE
Marie L Borum
No abstract text is available yet for this article.
May 2023: Gastroenterology & Hepatology
https://read.qxmd.com/read/37799458/examining-race-and-ethnicity-in-patients-with-inflammatory-bowel-disease
#34
JOURNAL ARTICLE
Gary R Lichtenstein
No abstract text is available yet for this article.
May 2023: Gastroenterology & Hepatology
https://read.qxmd.com/read/37799457/the-rise-of-private-equity-in-gastroenterology-practices
#35
JOURNAL ARTICLE
Jonathan A Busam, Eric D Shah
Private equity (PE) investment in gastroenterology practices has significantly increased over the past several years. Because PE firms are prevented legally from owning a medical practice in many states, they usually form a management services organization to oversee all nonclinical aspects of the practice, leaving all clinical functions to the physician owners. Gastroenterology practices have become attractive investments to PE firms because of the willingness of gastroenterologists to join a PE-backed practice and the potential to earn profits through consolidating the market...
May 2023: Gastroenterology & Hepatology
https://read.qxmd.com/read/37799456/advanced-combination-treatment-with-biologic-agents-and-novel-small-molecule-drugs-for-inflammatory-bowel-disease
#36
JOURNAL ARTICLE
Virginia Solitano, Christopher Ma, Jurij Han┼żel, Remo Panaccione, Brian G Feagan, Vipul Jairath
The use of combination therapy with a biologic agent and immunosuppressant has well-established efficacy and safety and is common practice in the management of inflammatory bowel disease (IBD). Current research has shifted focus toward the use of advanced combination treatment (ACT). This term was coined to describe combination therapy using 2 or more advanced treatments (biologic agents and/or oral small molecule drugs) with the aim of achieving optimal disease control in selected patients. An ACT approach may be particularly beneficial in patients with documented medically refractory IBD and in patients with a poor prognosis, extraintestinal manifestations, or concomitant immune-mediated inflammatory diseases...
May 2023: Gastroenterology & Hepatology
https://read.qxmd.com/read/37799455/potassium-competitive-acid-blockers-and-gastroesophageal-reflux-disease
#37
JOURNAL ARTICLE
David Armstrong
No abstract text is available yet for this article.
May 2023: Gastroenterology & Hepatology
https://read.qxmd.com/read/37799454/examining-the-new-definition-of-hepatorenal-syndrome-and-the-role-of-terlipressin
#38
JOURNAL ARTICLE
Robert S Brown
No abstract text is available yet for this article.
May 2023: Gastroenterology & Hepatology
https://read.qxmd.com/read/37799453/update-on-barrett-esophagus-diagnosis-and-management
#39
JOURNAL ARTICLE
Amitabh Chak
No abstract text is available yet for this article.
May 2023: Gastroenterology & Hepatology
https://read.qxmd.com/read/37711663/efficacy-and-safety-outcomes-up-to-4-years-of-treatment-with-filgotinib-200-mg-among-patients-with-ulcerative-colitis-results-from-the-selectionlte-study
#40
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
April 2023: Gastroenterology & Hepatology
journal
journal
41233
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.